


- 4-methyl-3- {[6-(methylthio)-4-quinazoliny]amino} phenol,
4-methyl-3- {[6-(methylsulfonyl)-4-quinazoliny]amino} phenol,
N-1,3-benzothiazol-5-yl-6-[(1,1-dimethylethyl)thio]-4-quinazolinamine,
N-1,3-benzothiazol-5-yl-6-[(1,1-dimethylethyl)sulfonyl]-4-quinazolinamine,
5 6-(*tert*-butylsulfonyl)-*N*-(5-fluoro-1*H*-indazol-3-yl)quinazolin-4-amine,
N-1,3-benzothiazol-5-yl-6-[(1-methylethyl)sulfonyl]-4-quinazolinamine,
2- {[4-(1,3-benzothiazol-5-ylamino)-6-quinazoliny]sulfonyl} ethanol,
N-1,3-benzothiazol-5-yl-6-(tetrahydro-2*H*-pyran-4-ylsulfonyl)-4-quinazolinamine,
N-1,3-benzothiazol-5-yl-6-(tetrahydro-2*H*-pyran-4-ylsulfonyl)-4-quinazolinamine,
10 2-((4-((4,5-dimethyl-1*H*-pyrazol-3-yl)amino)-7-methoxyquinazolin-6-yl)sulfonyl)ethanol,
N-(5-fluoro-1*H*-indazol-3-yl)-6-[(1-methylethyl)sulfonyl]-4-quinazolinamine,
N-(4,5-dimethyl-1*H*-pyrazol-3-yl)-6-[(1-methylethyl)sulfonyl]-4-quinazolinamine,
6-(*tert*-butylsulfonyl)-*N*-(5-(trifluoromethyl)-1*H*-pyrazol-3-yl)quinazolin-4-amine,
6-(*tert*-butylsulfonyl)-*N*-(1,3,4-trimethyl-1*H*-pyrazol-5-yl)quinazolin-4-amine,
15 *N*-(6-(*tert*-butylthio)-7-methoxyquinazolin-4-yl)benzo[*d*]thiazol-5-amine,
N-(6-(*tert*-butylsulfonyl)-7-methoxyquinazolin-4-yl)benzo[*d*]thiazol-5-amine,
N-(6-(isopropylsulfonyl)-7-methoxyquinazolin-4-yl)benzo[*d*]thiazol-5-amine,
4-(benzo[*d*]thiazol-5-ylamino)-6-(*tert*-butylsulfonyl)quinazolin-7-ol,
N-(6-(*tert*-butylsulfonyl)-7-ethoxyquinazolin-4-yl)benzo[*d*]thiazol-5-amine,
20 *N*-(6-(*tert*-butylsulfonyl)-7-ethoxyquinazolin-4-yl)-*N*-ethylbenzo[*d*]thiazol-5-amine,
2-((4-(benzo[*d*]thiazol-5-ylamino)-6-(*tert*-butylsulfonyl)quinazolin-7-yl)oxy)ethanol,
N-(6-(*tert*-butylsulfonyl)-7-(difluoromethoxy)quinazolin-4-yl)benzo[*d*]thiazol-5-amine,
N-(6-(*tert*-butylsulfonyl)-7-(2,2,2-trifluoroethoxy)quinazolin-4-yl)benzo[*d*]thiazol-5-amine,
N-(6-(*tert*-butylsulfonyl)-7-(methoxymethoxy)quinazolin-4-yl)benzo[*d*]thiazol-5-amine,
25 *N*-(6-(*tert*-butylsulfonyl)-7-(cyclohexylmethoxy)quinazolin-4-yl)benzo[*d*]thiazol-5-amine,
3-((4-(benzo[*d*]thiazol-5-ylamino)-6-(*tert*-butylsulfonyl)quinazolin-7-yl)oxy)propan-1-ol,
N-(6-(*tert*-butylsulfonyl)-7-((tetrahydro-2*H*-pyran-4-yl)oxy)quinazolin-4-yl)benzo[*d*]thiazol-
5-amine,
N-(6-(*tert*-butylsulfonyl)-7-(2-chloroethoxy)quinazolin-4-yl)benzo[*d*]thiazol-5-amine,
30 (R)-1-((4-(benzo[*d*]thiazol-5-ylamino)-6-(*tert*-butylsulfonyl)quinazolin-7-yl)oxy)propan-2-ol,
N-(6-(*tert*-butylsulfonyl)-7-propoxyquinazolin-4-yl)benzo[*d*]thiazol-5-amine,
N-(6-(*tert*-butylsulfonyl)-7-(2-(methylthio)ethoxy)quinazolin-4-yl)benzo[*d*]thiazol-5-amine,

Example 9

N-1,3-benzothiazol-5-yl-6-(tetrahydro-2*H*-pyran-4-ylsulfonyl)-4-quinazolinamine

Step 1. 3-{{[4-(1,3-benzothiazol-5-ylamino)-6-quinazolinyl]thio}}-3-methyl-1-butanol: To a solution of *N*-1,3-benzothiazol-5-yl-6-iodo-4-quinazolinamine (202 mg, 0.500 mmol), 3-mercapto-3-methyl-1-butanol (60 mg, 0.50 mmol), potassium *tert*-butoxide (168 mg, 1.50 mmol) and (oxydi-2,1-phenylene)bis(diphenyl phosphine) (27 mg, 0.05 mmol) in dioxane (4 mL) was added Pd_2dba_3 (46 mg, 0.05 mmol) and the mixture was sparged with N_2 for 10 min. The reaction was complete in 2 h. Solvent was removed and the crude material was purified *via* column chromatography (0 to 5% MeOH/ CH_2Cl_2) to afford 142 mg of the title compound (72%). MS: m/z : 397 $[\text{M}+\text{H}]^+$


Cesium carbonate may also be used as the base in these coupling reactions. An equivalent of triethamine may also be added when the starting quinazoline is an HCl salt.

Step 2. 3-{{[4-(1,3-benzothiazol-5-ylamino)-6-quinazolinyl]sulfonyl}}-3-methyl-1-butanol: 3-{{[4-(1,3-benzothiazol-5-ylamino)-6-quinazolinyl]thio}}-3-methyl-1-butanol (140 mg, 0.35 mmol) and oxone (434 mg, 0.71 mmol) were suspended in MeOH (2 mL) and the mixture was stirred at rt for 5 h. Upon filtration the cake was washed with MeOH and the filtrate was concentrated. The crude material was purified *via* column chromatography (0 to 8% MeOH/ CH_2Cl_2) to afford 3-{{[4-(1,3-benzothiazol-5-ylamino)-6-quinazolinyl]sulfonyl}}-3-methyl-1-butanol (67 mg, 0.15 mmol, 42% yield). MS: m/z : 429 $[\text{M}+\text{H}]^+$; ^1H NMR ($\text{DMSO}-d_6$) δ : 10.66 (s, 1H), 9.44 (s, 1H), 9.25 (d, $J = 1.5$ Hz, 1H), 8.76 (s, 1H), 8.64 (d, $J = 1.8$ Hz, 1H), 8.13 - 8.30 (m, 2H), 7.89 - 8.07 (m, 2H), 4.58 (t, $J = 4.8$ Hz, 1H), 3.58 (d, $J = 5.3$ Hz, 2H), 1.86 (t, $J = 6.9$ Hz, 2H), 1.34 (s, 6H).

EtOH and water (1:1) may also be used as the solvent mixture.

What is claimed is:

1. A compound according to Formula (I):



wherein:

R^1 is H, $-\text{SO}_2(\text{C}_1\text{-C}_4)\text{alkyl}$, $-\text{CO}(\text{C}_1\text{-C}_4)\text{alkyl}$, or $(\text{C}_1\text{-C}_4)\text{alkyl}$;

5 R^2 is $-\text{SR}^a$, $-\text{SOR}^a$, $-\text{SO}_2\text{R}^a$, $-\text{SO}_2\text{NH}_2$, or $-\text{SO}_2\text{NR}^b\text{R}^c$,

wherein R^a is $(\text{C}_1\text{-C}_6)\text{alkyl}$, $\text{halo}(\text{C}_1\text{-C}_6)\text{alkyl}$, $(\text{C}_3\text{-C}_7)\text{cycloalkyl}$, 4-7 membered heterocycloalkyl, aryl, or heteroaryl, wherein:

said $(\text{C}_1\text{-C}_6)\text{alkyl}$ is optionally substituted by one or two groups each independently selected from the group consisting of cyano, hydroxyl, $(\text{C}_1\text{-C}_6)\text{alkoxy}$,

10 $(\text{C}_1\text{-C}_6)\text{alkoxy}(\text{C}_2\text{-C}_6)\text{alkoxy}$, $-\text{CO}_2\text{H}$, $-\text{CO}_2(\text{C}_1\text{-C}_4)\text{alkyl}$, $-\text{SO}_2(\text{C}_1\text{-C}_4)\text{alkyl}$, $(\text{C}_3\text{-C}_7)\text{cycloalkyl}$, phenyl, 5-6 membered heteroaryl, 9-10 membered heteroaryl, 4-7 membered heterocycloalkyl and $(\text{phenyl})(\text{C}_1\text{-C}_4\text{ alkyl})\text{amino-}$, wherein said

$(\text{C}_3\text{-C}_7)\text{cycloalkyl}$, phenyl, $(\text{phenyl})(\text{C}_1\text{-C}_4\text{ alkyl})\text{amino-}$, 5-6 membered heteroaryl, 9-10 membered heteroaryl or 4-7 membered heterocycloalkyl is optionally substituted by 1-3

15 groups each independently selected from the group consisting of halogen, $-\text{CF}_3$, hydroxyl, amino, $((\text{C}_1\text{-C}_4)\text{alkyl})\text{amino-}$, $((\text{C}_1\text{-C}_4)\text{alkyl})((\text{C}_1\text{-C}_4)\text{alkyl})\text{amino-}$, $(\text{C}_1\text{-C}_4)\text{alkyl}$, $\text{phenyl}(\text{C}_1\text{-C}_4)\text{alkyl-}$, $\text{hydroxy}(\text{C}_1\text{-C}_4)\text{alkyl}$ and $(\text{C}_1\text{-C}_4)\text{alkoxy}$,

said $(\text{C}_3\text{-C}_7)\text{cycloalkyl}$ or 4-7 membered heterocycloalkyl is optionally substituted by 1-3 groups each independently selected from the group consisting of halogen, $-\text{CF}_3$,

20 hydroxyl, amino, $((\text{C}_1\text{-C}_4)\text{alkyl})\text{amino-}$, $((\text{C}_1\text{-C}_4)\text{alkyl})((\text{C}_1\text{-C}_4)\text{alkyl})\text{amino-}$, $(\text{C}_1\text{-C}_4)\text{alkyl}$, $\text{phenyl}(\text{C}_1\text{-C}_4)\text{alkyl-}$, $\text{hydroxy}(\text{C}_1\text{-C}_4)\text{alkyl-}$, oxo and $(\text{C}_1\text{-C}_4)\text{alkoxy}$, and

said aryl or heteroaryl is optionally substituted by 1-3 groups each independently selected from the group consisting of halogen, $-\text{CF}_3$, hydroxyl, amino,

$((\text{C}_1\text{-C}_4)\text{alkyl})\text{amino-}$, $((\text{C}_1\text{-C}_4)\text{alkyl})((\text{C}_1\text{-C}_4)\text{alkyl})\text{amino-}$, $(\text{C}_1\text{-C}_4)\text{alkyl}$,

25 $\text{phenyl}(\text{C}_1\text{-C}_4)\text{alkyl-}$, $\text{hydroxy}(\text{C}_1\text{-C}_4)\text{alkyl-}$ and $(\text{C}_1\text{-C}_4)\text{alkoxy}$;

R^b is $(\text{C}_1\text{-C}_6)\text{alkyl}$ or 4-7 membered heterocycloalkyl, wherein:

said (C₁-C₆)alkyl is optionally substituted by one or two groups each independently selected from the group consisting of hydroxyl, (C₁-C₆)alkoxy, (C₁-C₆)alkoxy(C₂-C₆)alkoxy, -CO₂H, -CO₂(C₁-C₄)alkyl, (C₁-C₄ alkyl)amino-, (C₁-C₄ alkyl)(C₁-C₄ alkyl)amino-, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl, wherein said 5-6 membered heteroaryl or 4-7 membered heterocycloalkyl is optionally substituted by 1-3 groups each independently selected from the group consisting of halogen, (C₁-C₄)alkyl, hydroxy(C₁-C₄)alkyl and (C₁-C₄)alkoxy, said 4-7 membered heterocycloalkyl is optionally substituted by 1-3 groups each independently selected from the group consisting of hydroxyl, amino, (C₁-C₄)alkyl, (C₁-C₄)alkoxycarbonyl-, hydroxy(C₁-C₄)alkyl-, oxo and (C₁-C₄)alkoxy, and R^c is H, (C₁-C₄)alkoxy or (C₁-C₆)alkyl; or R^b and R^c taken together with the nitrogen atom to which they are attached form a 3-7 membered heterocycloalkyl group, optionally containing one or two additional ring heteroatoms each independently selected from nitrogen and oxygen, wherein said 3-7 membered heterocycloalkyl is optionally substituted by 1-3 groups each independently selected from the group consisting of (C₁-C₄)alkyl, hydroxy, -CO₂H and -CO(C₁-C₄)alkyl; R³ is H, halogen, hydroxy, (C₁-C₄)alkyl-, (C₂-C₄)alkenyl-, halo(C₁-C₄)alkyl-, hydroxy(C₂-C₄)alkenyl-, (C₁-C₄)alkoxy-, (C₂-C₄)alkenyloxy-, halo(C₁-C₄)alkoxy-, (C₁-C₄)alkoxy(C₁-C₆)alkyl-, halo(C₁-C₄)alkoxy(C₁-C₆)alkyl-, (C₁-C₄)alkoxy(C₂-C₆)alkoxy-, halo(C₁-C₄)alkoxy(C₂-C₆)alkoxy-, hydroxy(C₁-C₆)alkyl-, hydroxy(C₂-C₆)alkoxy-, hydroxy(C₃-C₄)alkenyl-, cyano(C₁-C₄)alkyl-, cyano(C₂-C₆)alkoxy-, (C₁-C₄)alkyl-thio-(C₂-C₄)alkoxy, (C₁-C₄)alkyl-sulfonyl-(C₂-C₄)alkoxy-, carboxy-(C₁-C₆)alkoxy-, carboxy-(C₂-C₄)alkenyl-oxy-, (C₁-C₄)alkoxycarbonyl(C₁-C₆)alkoxy-, (C₁-C₄)alkoxycarbonyl(C₂-C₄)alkenyl-oxy-, carboxy(C₂-C₄)alkenyl-, (C₁-C₄)alkoxycarbonyl(C₂-C₄)alkenyl-, aminocarbonyl(C₁-C₆)alkoxy-, aminocarbonyl(C₂-C₄)alkenyl-oxy-, (C₃-C₆)cycloalkyl(C₁-C₄)alkoxy-, (C₃-C₆)cycloalkoxy-, 4-6 membered-heterocycloalkyl(C₁-C₄)alkoxy-, or 4-6 membered-heterocycloalkyl-oxy-, wherein the halo(C₁-C₄)alkyl-, halo(C₁-C₄)alkoxy-, halo(C₁-C₄)alkoxy(C₁-C₆)alkyl-, or halo(C₁-C₄)alkoxy(C₂-C₆)alkoxy- groups contain 2 or 3 halo atoms,

wherein the (C₃-C₆)cycloalkyl moiety of the (C₃-C₆)cycloalkyl(C₁-C₄)alkoxy- or (C₃-C₆)cycloalkoxy- is optionally substituted by a group selected from the group consisting of cyano, halo, hydroxyl, (C₁-C₆)alkoxy and (C₁-C₄)alkoxy(C₂-C₆)alkoxy, and

wherein the 4-6 membered heterocycloalkyl moiety of the 4-6 membered heterocycloalkyl(C₁-C₄)alkoxy-, or 4-6 membered-heterocycloalkyl-oxy- is optionally substituted by a group selected from the group consisting of cyano, halo, hydroxyl, (C₁-C₆)alkoxy and (C₁-C₄)alkoxy(C₂-C₆)alkoxy;

Z is phenyl or aryl(C₁-C₄)alkyl-, wherein in the phenyl group or the aryl moiety of the aryl(C₁-C₄)alkyl- group is substituted by R⁴, R⁵, R⁶ and R⁷, wherein:

R⁴ is H, halogen, cyano, (C₁-C₄)alkyl, halo(C₁-C₄)alkyl, (C₁-C₄)alkoxy, phenoxy, phenyl(C₁-C₄)alkoxy, hydroxyl, hydroxy(C₁-C₄)alkyl-, or aminocarbonyl, wherein the phenyl moiety of said phenoxy or phenyl(C₁-C₄)alkoxy- is optionally substituted by 1-3 substituents each independently selected from the group consisting of halogen, -CF₃, (C₁-C₄)alkyl and (C₁-C₄)alkoxy; and

each of R⁵, R⁶ and R⁷ is independently selected from the group consisting of H, hydroxyl, halogen, -CF₃, hydroxy(C₁-C₄)alkyl, (C₁-C₄)alkyl and (C₁-C₄)alkoxy; or

Z is phenyl or pyridyl, substituted by R⁸, R⁹ and R¹⁰, wherein:


R⁸ and R⁹ are located on adjacent atoms and taken together with the atoms to which they are attached form a 5-membered ring containing 1, 2 or 3 heteroatoms each independently selected from N, O and S, which 5-membered ring is substituted by R¹¹;

wherein one of R¹⁰ or R¹¹ is H, halogen, cyano, (C₁-C₄)alkyl, halo(C₁-C₄)alkyl, (C₁-C₄)alkoxy, phenoxy, phenyl(C₁-C₄)alkoxy, hydroxyl, hydroxy(C₁-C₄)alkyl-, or aminocarbonyl, where the phenyl moiety of said phenoxy or phenyl(C₁-C₄)alkoxy is optionally substituted by 1-3 substituents each independently selected from the group consisting of halogen, -CF₃, (C₁-C₄)alkyl and (C₁-C₄)alkoxy; and

the other of R¹⁰ or R¹¹ is H, hydroxyl, halogen, -CF₃, hydroxy(C₁-C₄)alkyl, (C₁-C₄)alkyl or (C₁-C₄)alkoxy; or

Z is pyrazolyl, having the formula:

R¹² is H, methyl or hydroxymethyl;



wherein:

R¹³ is methyl, trifluoromethyl or hydroxymethyl;

R¹⁴ is H, OH, or (C₁-C₃)alkyl; or

R¹² and R¹³, taken together with the atoms to which they are attached, form a 6-membered ring substituted by R¹⁵ and R¹⁶, wherein the 6-membered ring optionally contains 1 nitrogen atom;

wherein R¹⁵ and R¹⁶ are each independently selected from the group consisting of H, halogen, cyano, (C₁-C₄)alkyl, halo(C₁-C₄)alkyl, (C₁-C₄)alkoxy, phenoxy, phenyl(C₁-C₄)alkoxy, hydroxyl, hydroxy(C₁-C₄)alkyl-, and aminocarbonyl, wherein the phenyl moiety of said phenoxy or phenyl(C₁-C₄)alkoxy is optionally substituted by 1-3 substituents each independently selected from the group consisting of halogen, -CF₃, (C₁-C₄)alkyl and (C₁-C₄)alkoxy;

provided that the compound is not:

ethyl 5-{{4-[(3-chloro-4-fluorophenyl)amino]-7-(methoxy)-6-quinazolinyl}thio}pentanoate,

ethyl 4-{{4-[(3-chloro-4-fluorophenyl)amino]-7-(methoxy)-6-quinazolinyl}thio}butanoate,

ethyl 7-{{4-[(3-chloro-4-fluorophenyl)amino]-7-(methoxy)-6-quinazolinyl}thio}heptanoate,

N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[(trifluoromethyl)sulfonyl]-4-quinazolinamine,

ethyl 7-{{4-[(3-chloro-4-fluorophenyl)amino]-7-(methoxy)-6-quinazolinyl}sulfonyl}heptanoate,

N-[(3,4-difluorophenyl)methyl]-6-[(methyl)sulfonyl]-4-quinazolinamine,

3-methoxy-5-[[6-[(methylthio)]-4-quinazolinyl]amino]-phenol,

3-methoxy-5-[[6-[(methylsulfinyl)]-4-quinazolinyl]amino]-phenol,

N-[(3,4-dichlorophenyl)methyl]-6-(methylthio)-4-quinazolinamine,

N-[(3-fluoro-4-methoxyphenyl)methyl]-6-(methylthio)-4-quinazolinamine,

6-(methylthio)-*N*-[4-(phenylmethoxy)phenyl]-4-quinazolinamine,

6-(methylsulfonyl)-*N*-[4-(phenylmethoxy)phenyl]-4-quinazolinamine,

6-(methylsulfinyl)-*N*-[4-(phenylmethoxy)phenyl]-4-quinazolinamine,

6-(methylthio)-*N*-(4-(phenoxyphenyl)-4-quinazolinamine,

N-(3-(methylphenyl)-6-(methylthio)-4-quinazolinamine,

or a salt thereof.

2. The compound or salt according to claim 1, wherein:

R¹ is H, -SO₂(C₁-C₄)alkyl, -CO(C₁-C₄)alkyl, or (C₁-C₄)alkyl;

R² is -SR^a, -SOR^a, or -SO₂R^a, wherein R^a is (C₁-C₆)alkyl, halo(C₁-C₆)alkyl, (C₃-C₇)cycloalkyl, 4-7 membered heterocycloalkyl, aryl, or heteroaryl, wherein:

said (C₁-C₆)alkyl is optionally substituted by one or two groups each independently
 5 selected from cyano, hydroxyl, (C₁-C₆)alkoxy, (C₁-C₆)alkoxy(C₂-C₆)alkoxy, -CO₂H, -CO₂(C₁-C₄)alkyl, -SO₂(C₁-C₄)alkyl, (C₃-C₇)cycloalkyl, phenyl, 5-6 membered heteroaryl, 9-10 membered heteroaryl, 4-7 membered heterocycloalkyl and (phenyl)(C₁-C₄ alkyl)amino-, wherein said (C₃-C₇)cycloalkyl, phenyl, (phenyl)(C₁-C₄ alkyl)amino-, 5-6 membered heteroaryl, 9-10 membered heteroaryl or 4-7
 10 membered heterocycloalkyl is optionally substituted by 1-3 groups each independently selected from halogen, -CF₃, hydroxyl, amino, ((C₁-C₄)alkyl)amino-, ((C₁-C₄)alkyl)((C₁-C₄)alkyl)amino-, (C₁-C₄)alkyl, phenyl(C₁-C₄)alkyl-, hydroxy(C₁-C₄)alkyl and (C₁-C₄)alkoxy,

said (C₃-C₇)cycloalkyl or 4-7 membered heterocycloalkyl is optionally substituted
 15 by 1-3 groups each independently selected from halogen, -CF₃, hydroxyl, amino, ((C₁-C₄)alkyl)amino-, ((C₁-C₄)alkyl)((C₁-C₄)alkyl)amino-, (C₁-C₄)alkyl, phenyl(C₁-C₄)alkyl-, hydroxy(C₁-C₄)alkyl-, oxo and (C₁-C₄)alkoxy, and

said aryl or heteroaryl is optionally substituted by 1-3 groups each independently
 20 selected from halogen, -CF₃, hydroxyl, amino, ((C₁-C₄)alkyl)amino-, ((C₁-C₄)alkyl)((C₁-C₄)alkyl)amino-, (C₁-C₄)alkyl, phenyl(C₁-C₄)alkyl-, hydroxy(C₁-C₄)alkyl- and (C₁-C₄)alkoxy;

R³ is H, halogen, hydroxy, (C₁-C₄)alkyl-, (C₂-C₄)alkenyl-, halo(C₁-C₄)alkyl-, (C₁-C₄)alkoxy-, halo(C₁-C₄)alkoxy-, (C₁-C₄)alkoxy(C₁-C₆)alkyl-, halo(C₁-C₄)alkoxy(C₁-C₆)alkyl-, (C₁-C₄)alkoxy(C₂-C₆)alkoxy-,
 25 halo(C₁-C₄)alkoxy(C₂-C₆)alkoxy-, hydroxy(C₁-C₆)alkyl-, hydroxy(C₂-C₆)alkoxy-, cyano(C₁-C₄)alkyl-, cyano(C₂-C₆)alkoxy-, carboxy-(C₁-C₆)alkoxy-, (C₁-C₄)alkoxycarbonyl(C₁-C₆)alkoxy-, (C₃-C₆)cycloalkyl(C₁-C₄)alkoxy-, (C₃-C₆)cycloalkoxy-, 4-6 membered-heterocycloalkyl(C₁-C₄)alkoxy-, or 4-6 membered-heterocycloalkoxy-,

wherein the halo(C₁-C₄)alkyl-, halo(C₁-C₄)alkoxy-, halo(C₁-C₄)alkoxy(C₁-C₆)alkyl-, or halo(C₁-C₄)alkoxy(C₂-C₆)alkoxy- groups contain 2 or 3 halo atoms; and

wherein the (C₃-C₆)cycloalkyl moiety of the (C₃-C₆)cycloalkyl(C₁-C₄)alkoxy- or (C₃-C₆)cycloalkoxy-, is optionally substituted by a group selected from cyano, halo, hydroxyl, (C₁-C₆)alkoxy and (C₁-C₄)alkoxy(C₂-C₆)alkoxy;

wherein the 4-6 membered-heterocycloalkyl moiety of the 4-6 membered-heterocycloalkyl(C₁-C₄)alkoxy-, or 4-6 membered-heterocycloalkoxy-, is optionally substituted by a group selected from cyano, halo, hydroxyl, (C₁-C₆)alkoxy and (C₁-C₄)alkoxy(C₂-C₆)alkoxy;

Z is phenyl or aryl(C₁-C₄)alkyl-, substituted by R⁴, R⁵, R⁶ and R⁷, wherein:

R⁴ is H, halogen, cyano, (C₁-C₄)alkyl, halo(C₁-C₄)alkyl, (C₁-C₄)alkoxy, phenoxy, phenyl(C₁-C₄)alkoxy, hydroxyl, hydroxy(C₁-C₄)alkyl-, or aminocarbonyl, wherein the phenyl moiety of said phenoxy or phenyl(C₁-C₄)alkoxy- is optionally substituted by 1-3 substituents each independently selected from halogen, -CF₃, (C₁-C₄)alkyl and (C₁-C₄)alkoxy; and


each of R⁵, R⁶ and R⁷ is independently selected from H, hydroxyl, halogen, -CF₃, hydroxy(C₁-C₄)alkyl, (C₁-C₄)alkyl and (C₁-C₄)alkoxy; or

Z is phenyl or pyridyl substituted by R⁸, R⁹ and R¹⁰, wherein:

R⁸ and R⁹ are located on adjacent atoms and taken together with the atoms to which they are attached form a 5-membered heterocyclic group containing 1, 2 or 3 heteroatoms each independently selected from N, O and S, which 5-membered heterocyclic group is substituted by R¹¹;

wherein one of R¹⁰ or R¹¹ is H, halogen, cyano, (C₁-C₄)alkyl, halo(C₁-C₄)alkyl, (C₁-C₄)alkoxy, phenoxy, phenyl(C₁-C₄)alkoxy, hydroxyl, hydroxy(C₁-C₄)alkyl-, or aminocarbonyl, where the phenyl moiety of said phenoxy or phenyl(C₁-C₄)alkoxy is optionally substituted by 1-3 substituents each independently selected from halogen, -CF₃, (C₁-C₄)alkyl and (C₁-C₄)alkoxy; and

the other of R¹⁰ or R¹¹ is H, hydroxyl, halogen, -CF₃, hydroxy(C₁-C₄)alkyl, (C₁-C₄)alkyl or (C₁-C₄)alkoxy; or



Z is pyrazolyl, having the formula:

wherein:

R^{12} is H, methyl or hydroxymethyl;

R^{13} is methyl, trifluoromethyl or hydroxymethyl;

R^{14} is H, OH, or (C_1-C_3) alkyl; or

5 R^{12} and R^{13} , taken together with the atoms to which they are attached, form a 6 membered carbocyclic ring or heterocyclic ring substituted by R^{15} and R^{16} , wherein the heterocyclic ring contains 1 nitrogen atom;

wherein R^{15} and R^{16} are each independently selected from H, halogen, cyano, (C_1-C_4) alkyl, halo (C_1-C_4) alkyl, (C_1-C_4) alkoxy, phenoxy, phenyl (C_1-C_4) alkoxy, hydroxyl, 10 hydroxy (C_1-C_4) alkyl-, and aminocarbonyl, wherein the phenyl moiety of said phenoxy or phenyl (C_1-C_4) alkoxy is optionally substituted by 1-3 substituents each independently selected from halogen, $-CF_3$, (C_1-C_4) alkyl and (C_1-C_4) alkoxy.

3. The compound or salt according to claim 1 or claim 2, wherein R^1 is H.

15 4. The compound or salt according to any one of claims 1-2, wherein R^2 is or $-SO_2R^a$.

5. The compound or salt according to any one of claims 1-4, wherein R^a is an optionally substituted (C_1-C_6) alkyl or 5-6-membered heterocycloalkyl group, wherein:

20 said (C_1-C_6) alkyl is optionally substituted by a substituent selected from the group consisting of hydroxyl, (C_1-C_2) alkoxy, (C_1-C_2) alkoxy (C_2-C_3) alkoxy-, amino, (C_1-C_3) alkylamino-, (C_1-C_3) alkyl (C_1-C_2) alkylamino-, 5-6-membered heterocycloalkyl (optionally substituted by (C_1-C_4) alkyl), and C_3-C_6 cycloalkyl (optionally substituted by (C_1-C_4) alkyl or hydroxy (C_1-C_4) alkyl), and

25 said 5-6 membered heterocycloalkyl is optionally substituted by 1 or 2 groups each independently selected from the group consisting of halogen, (C_1-C_4) alkyl, and hydroxy (C_1-C_4) alkyl;

wherein any of said 5-6 membered heterocycloalkyl contains 1 heteroatom selected from N, O and S.

6. The compound or salt according to any one of claims 1-4, wherein R^a is a (C₁-C₆)alkyl group optionally substituted by a substituent selected from the group consisting of hydroxyl, (C₁-C₂)alkoxy, and (C₁-C₂)alkoxy(C₂-C₃)alkoxy- or R^a is a 5-6-membered heterocycloalkyl group optionally substituted by 1 or 2 independently selected (C₁-C₄)alkyl groups.

7. The compound or salt according to any one of claims 1-4, wherein R^a is an unsubstituted (C₁-C₅)alkyl.

10

8. The compound or salt according to any one of claims 1-4, wherein R^a is -CH₃, -CH(CH₃)₂, or -C(CH₃)₃.

9. The compound or salt according to any one of claims 1-4, wherein R^a is -CH₂CH₂OH, -C(CH₃)₂CH₂CH₂OH, or tetrahydro-2H-pyran-4-yl.

15

10. The compound or salt according to claim 1 or claim 3, wherein R^b is a (C₁-C₄)alkyl substituted by hydroxyl, (C₁-C₂)alkoxy, (C₁-C₃ alkyl)amino-, (C₁-C₃ alkyl)(C₁-C₂ alkyl)amino-, a 4-6-membered heterocycloalkyl, optionally substituted by (C₁-C₄)alkyl, or a 5-6-membered heteroaryl, optionally substituted by (C₁-C₄)alkyl.

20

11. The compound or salt according to claim 1 or claim 3, wherein R^b is -CH₃, -CH(CH₃)₂, -CH₂CH₂OH, -CH₂CH₂OCH₃, -CH₂C(CH₃)₂OH, -CH₂CH(CH₃)OH, -CH₂CH₂N(CH₃)₂, oxetan-3-yl, tetrahydro-2H-pyran-4-yl, -CH₂-tetrahydro-2H-pyran-4-yl, or -CH₂CH₂-1H-tetrazol-5-yl.

25

12. The compound or salt according to any one of claims 1, 3, 10 or 11, wherein R^c is H or CH₃.

30

13. The compound or salt according to claim 1 or claim 3, wherein R^b and R^c taken together with the nitrogen atom to which they are attached form a 5-6-membered

heterocycloalkyl, optionally containing 1 additional heteroatom selected from N and O, and optionally substituted by a hydroxyl, (C₁-C₄)alkyl, carboxy or (C₁-C₄)alkylcarbonyl-group.

5 14. The compound or salt according to claim 1 or claim 3, wherein R^b and R^c taken together with the nitrogen atom to which they are attached form a morpholin-4-yl, 4-methylcarbonyl-piperazin-1-yl, pyrrolidin-1-yl, 3-hydroxy-pyrrolidin-1-yl, or 2-(carboxy)-1-pyrrolidin-1-yl group.

10 15. The compound or salt according to any one of claims 1-14, wherein R³ is H, halogen, hydroxy, (C₁-C₄)alkyl-, (C₂-C₄)alkenyl-, halo(C₁-C₄)alkyl-, (C₁-C₄)alkoxy-, halo(C₁-C₄)alkoxy-, (C₃-C₆)cycloalkyl(C₁-C₄)alkoxy-, 5-6-membered-heterocycloalkyl-oxy-, (C₁-C₄)alkoxy(C₁-C₆)alkyl-, (C₁-C₄)alkoxy(C₂-C₆)alkoxy-, carboxy-(C₁-C₆)alkoxy-, (C₁-C₄)alkoxycarbonyl(C₁-C₆)alkoxy-, hydroxy(C₁-C₆)alkyl-, or hydroxy(C₂-C₆)alkoxy-.

15 16. The compound or salt according to any one of claims 1-14, wherein R³ is H.

 17. The compound or salt according to any one of claims 1-14, wherein R³ is halogen, hydroxy, (C₁-C₃)alkyl-, (C₂-C₃)alkenyl-, halo(C₁-C₂)alkyl-,
20 hydroxy(C₂-C₃)alkenyl-, (C₁-C₄)alkoxy-, (C₂-C₃)alkenyl-oxy-, halo(C₁-C₃)alkoxy-, (C₅-C₆)cycloalkyl(C₁-C₃)alkoxy-, 5-6-membered-heterocycloalkyl-oxy-, (C₁-C₃)alkoxy(C₁-C₄)alkyl-, (C₁-C₃)alkoxy(C₂-C₄)alkoxy-, (C₁-C₃)alkyl-thio-(C₂-C₄)alkoxy-, (C₁-C₃)alkyl-sulfonyl-(C₂-C₄)alkoxy-, carboxy-(C₁-C₄)alkoxy-, carboxy-(C₂-C₄)alkenyl-oxy-, (C₁-C₃)alkoxycarbonyl(C₁-C₄)alkoxy-,
25 (C₁-C₃)alkoxycarbonyl(C₂-C₄)alkenyl-oxy-, aminocarbonyl(C₁-C₄)alkoxy-, aminocarbonyl(C₂-C₄)alkenyl-oxy-, hydroxy(C₂-C₄)alkoxy-, or hydroxy(C₂-C₄)alkenyl-oxy-.

 18. The compound or salt according to any one of claims 1-14, wherein R³ is
30 halogen, hydroxy, (C₁-C₃)alkyl-, (C₂-C₃)alkenyl-, halo(C₁-C₂)alkyl-, (C₁-C₄)alkoxy-, halo(C₁-C₃)alkoxy-, (C₅-C₆)cycloalkyl(C₁-C₃)alkoxy-, 5-6-membered-heterocycloalkyl-

oxy-, (C₁-C₃)alkoxy(C₁-C₄)alkyl-, (C₁-C₃)alkoxy(C₂-C₄)alkoxy-, carboxy-(C₁-C₄)alkoxy-, (C₁-C₃)alkoxycarbonyl(C₁-C₄)alkoxy-, or hydroxy(C₂-C₄)alkoxy-.

19. The compound or salt according to any one of claims 1-14, wherein R³ is
 5 chloro, -CH₂CH₃, -CH=CH₂, -CH=CHCH₂OH, -OCH=CH₂, -OCH=CH-CO₂H,
 -OCH=CH-CO₂CH₃, -OCH=CH-CONH₂, -OH, -OCH₃, -OCF₂H, -OCH(CH₃)₂,
 -OCH₂CH₃, -OCH₂CF₃, -OCH₂CH₂CH₃, -OCH₂CH₂Cl, -OCH₂CH₂Br, -OCH₂CH₂SCH₃,
 -OCH₂CH₂SO₂CH₃, -OCH₂CH₂SO₂CH(CH₃)₂, -OCH₂CH₂OH, -OCH₂CH₂CH₂OH,
 -OCH₂CH₂OCH₃, -OC(CH₃)₂CH₂OH, -OCH(CH₃)CH₂OH, -OCH(CH₃)CO₂CH₃,
 10 -OCH₂CH(CH₃)OH, -OC(CH₃)₂CO₂CH₂CH₃, -OCH₂CO₂H, -OCH₂CONH₂, -OCH₂-
 cyclohexyl, or -O-tetrahydro-2H-pyran-4-yl.

20. The compound or salt according to any one of claims 1-19, wherein Z is
 phenyl, substituted by 1 or 2 substituents each independently selected from the group
 15 consisting of hydroxyl, halogen, hydroxy(C₁-C₄)alkyl, (C₁-C₄)alkyl, and (C₁-C₄)alkoxy.

21. The compound or salt according to any one of claims 1-19, wherein Z is
 2-methyl-5-hydroxy-phenyl, 2-fluoro-4-chloro-phenyl, 3-methoxy-4-chloro-phenyl, or
 3-hydroxy-4-chloro-phenyl.


20

22. The compound or salt according to any one of claims 1-19, wherein Z is phenyl
 or pyridyl substituted by R⁸, R⁹ and R¹⁰, wherein:

R⁸ and R⁹ are located on adjacent carbon atoms and taken together with the atoms
 to which they are attached form a 5-membered ring containing 1, 2 or 3 heteroatoms each
 25 independently selected from N, O and S, which 5-membered ring is substituted by R¹¹;

wherein one of R¹⁰ or R¹¹ is H, halogen, cyano, (C₁-C₄)alkyl, halo(C₁-C₄)alkyl,
 (C₁-C₄)alkoxy, phenoxy, phenyl(C₁-C₄)alkoxy, hydroxyl, hydroxy(C₁-C₄)alkyl-, or
 aminocarbonyl, where the phenyl moiety of said phenoxy or phenyl(C₁-C₄)alkoxy is
 optionally substituted by 1-3 substituents each independently selected from the group
 30 consisting of halogen, -CF₃, (C₁-C₄)alkyl and (C₁-C₄)alkoxy; and

the other of R¹⁰ or R¹¹ is H, hydroxyl, halogen, -CF₃, hydroxy(C₁-C₄)alkyl,
 (C₁-C₄)alkyl or (C₁-C₄)alkoxy;



or Z is pyrazolyl, having the formula:

wherein:

R^{12} is H, methyl or hydroxymethyl;

R^{13} is methyl, trifluoromethyl or hydroxymethyl;

R^{14} is H, OH, or (C_1-C_3) alkyl;

- 5 or R^{12} and R^{13} , taken together with the atoms to which they are attached, form a 6-membered ring substituted by R^{15} and R^{16} , wherein the 6-membered ring contains 1 nitrogen atom;

wherein R^{15} and R^{16} are each independently selected from the group consisting of H, halogen, cyano, (C_1-C_4) alkyl, halo (C_1-C_4) alkyl, (C_1-C_4) alkoxy, phenoxy,
 10 phenyl (C_1-C_4) alkoxy, hydroxyl, hydroxy (C_1-C_4) alkyl-, and aminocarbonyl, wherein the phenyl moiety of said phenoxy or phenyl (C_1-C_4) alkoxy is optionally substituted by 1-3 substituents each independently selected from the group consisting of halogen, $-CF_3$, (C_1-C_4) alkyl and (C_1-C_4) alkoxy.

- 15 23. The compound or salt according to any one of claims 1-19, wherein Z is benzothiazolyl, optionally substituted by 1-3 substituents independently selected from the group consisting of halogen, (C_1-C_4) alkyl, halo (C_1-C_4) alkyl or (C_1-C_4) alkoxy.

- 20 24. The compound or salt according to any one of claims 1-19, wherein Z is benzo[d]thiazol-5-yl.

25 25. The compound or salt according to any one of claims 1-19, wherein Z is pyrazolyl, R^{12} is H or methyl, R^{13} is methyl or trifluoromethyl, and R^{14} is H or methyl.

- 25 26. The compound or salt according to any one of claims 1-19, wherein Z is pyrazolyl, R^{12} and R^{13} are each methyl, and R^{14} is H.

27. The compound or salt according to any one of claims 1-19, wherein Z is an optionally substituted indazolyl or pyrazolo[3,4-*b*]pyridinyl, each optionally substituted by

hydroxyl, chloro, fluoro, -CF₃, cyano, hydroxymethyl-, methyl, methoxy or aminocarbonyl.

28. The compound or salt according to any one of claims 1-19, wherein Z is
5 5-fluoro-1*H*-indazol-3-yl, 1*H*-indazol-6-yl or 3-methyl-1*H*-indazol-6-yl.

29. The compound or salt according to any one of claims 1-28, wherein the salt is a pharmaceutically acceptable salt of said compound.

10 30. A compound of any one of Examples 1-80, or a pharmaceutically acceptable salt thereof.

31. A compound which is:
N-1,3-benzothiazol-5-yl-6-[(1,1-dimethylethyl)sulfonyl]-4-quinazolinamine,
15 *N*-1,3-benzothiazol-5-yl-6-[(1-methylethyl)sulfonyl]-4-quinazolinamine,
N-(6-(*tert*-butylsulfonyl)-7-methoxyquinazolin-4-yl)benzo[*d*]thiazol-5-amine, or
2-((4-(benzo[*d*]thiazol-5-ylamino)-6-(*tert*-butylsulfonyl)quinazolin-7-
yl)oxy)ethanol,
or a pharmaceutically acceptable salt, thereof.

20 32. A pharmaceutical composition comprising the compound or pharmaceutically acceptable salt thereof according to any one of claims 29-31, and one or more pharmaceutically acceptable excipients.

33. A method of treating a disease mediated by inhibition of RIP2 kinase comprising administering a therapeutically effective amount of the compound or pharmaceutically acceptable salt thereof according to any one of claims 29-31 to a human in need thereof.

34. A compound or pharmaceutically acceptable salt thereof according to any one of claims 29-31 for use in the treatment of a disease mediated by inhibition of RIP2 kinase.


35. Use of the compound, or pharmaceutically acceptable salt thereof, according to any of claims 29-31 in the manufacture of a medicament for the treatment of a disease mediated by inhibition of RIP2 kinase.

36. The method, compound or use according to claims 33-35, wherein the disease mediated by inhibition of RIP2 kinase is selected from uveitis, interleukin-1 converting enzyme associated fever syndrome, dermatitis, acute lung injury, type 2 diabetes mellitus, arthritis, rheumatoid arthritis, an inflammatory bowel disorder, ulcerative colitis, Crohn's disease, early-onset and extra-intestinal inflammatory bowel disease, prevention of ischemia reperfusion injury in solid organ transplant, non-alcohol steatohepatitis, alcohol
5 steatohepatitis, autoimmune hepatitis, asthma, graft versus host disease, systemic lupus
10 erythematosus, multiple sclerosis, sarcoidosis, Blau syndrome/early-onset sarcoidosis, Wegner's granulomatosis, and interstitial pulmonary disease.

- 4-methyl-3- {[6-(methylthio)-4-quinazoliny]amino} phenol,
 4-methyl-3- {[6-(methylsulfonyl)-4-quinazoliny]amino} phenol,
N-1,3-benzothiazol-5-yl-6-[(1,1-dimethylthyl)thio]-4-quinazolinamine,
N-1,3-benzothiazol-5-yl-6-[(1,1-dimethylethyl)sulfonyl]-4-quinazolinamine,
 5 6-(*tert*-butylsulfonyl)-*N*-(5-fluoro-1*H*-indazol-3-yl)quinazolin-4-amine,
N-1,3-benzothiazol-5-yl-6-[(1-methylthyl)sulfonyl]-4-quinazolinamine,
 2- {[4-(1,3-benzothiazol-5-ylamino)-6-quinazoliny]sulfonyl} ethanol,
N-1,3-benzothiazol-5-yl-6-(tetrahydro-2*H*-pyran-4-ylsulfonyl)-4-quinazolinamine,
 10 2-((4-((4,5-dimethyl-1*H*-pyrazol-3-yl)amino)-7-methoxyquinazolin-6-yl)sulfonyl)ethanol,
N-(5-fluoro-1*H*-indazol-3-yl)-6-[(1-methylthyl)sulfonyl]-4-quinazolinamine,
N-(4,5-dimethyl-1*H*-pyrazol-3-yl)-6-[(1-methylethyl)sulfonyl]-4-quinazolinamine,
 6-(*tert*-butylsulfonyl)-*N*-(5-(trifluoromethyl)-1*H*-pyrazol-3-yl)quinazolin-4-amine,
 6-(*tert*-butylsulfonyl)-*N*-(1,3,4-trimethyl-1*H*-pyrazol-5-yl)quinazolin-4-amine,
 15 *N*-(6-(*tert*-butylthio)-7-methoxyquinazolin-4-yl)benzo[*d*]thiazol-5-amine,
N-(6-(*tert*-butylsulfonyl)-7-methoxyquinazolin-4-yl)benzo[*d*]thiazol-5-amine,
N-(6-(isopropylsulfonyl)-7-methoxyquinazolin-4-yl)benzo[*d*]thiazol-5-amine,
 4-(benzo[*d*]thiazol-5-ylamino)-6-(*tert*-butylsulfonyl)quinazolin-7-ol,
N-(6-(*tert*-butylsulfonyl)-7-ethoxyquinazolin-4-yl)benzo[*d*]thiazol-5-amine,
 20 *N*-(6-(*tert*-butylsulfonyl)-7-ethoxyquinazolin-4-yl)-*N*-ethylbenzo[*d*]thiazol-5-amine,
 2-((4-(benzo[*d*]thiazol-5-ylamino)-6-(*tert*-butylsulfonyl)quinazolin-7-yl)oxy)ethanol,
N-(6-(*tert*-butylsulfonyl)-7-(difluoromethoxy)quinazolin-4-yl)benzo[*d*]thiazol-5-amine,
N-(6-(*tert*-butylsulfonyl)-7-(2,2,2-trifluoroethoxy)quinazolin-4-yl)benzo[*d*]thiazol-5-amine,
N-(6-(*tert*-butylsulfonyl)-7-(methoxymethoxy)quinazolin-4-yl)benzo[*d*]thiazol-5-amine,
 25 *N*-(6-(*tert*-butylsulfonyl)-7-(cyclohexylmethoxy)quinazolin-4-yl)benzo[*d*]thiazol-5-amine,
 3-((4-(benzo[*d*]thiazol-5-ylamino)-6-(*tert*-butylsulfonyl)quinazolin-7-yl)oxy)propan-1-ol,
N-(6-(*tert*-butylsulfonyl)-7-((tetrahydro-2*H*-pyran-4-yl)oxy)quinazolin-4-yl)benzo[*d*]thiazol-
 5-amine,
N-(6-(*tert*-butylsulfonyl)-7-(2-chloroethoxy)quinazolin-4-yl)benzo[*d*]thiazol-5-amine,
 30 (R)-1-((4-(benzo[*d*]thiazol-5-ylamino)-6-(*tert*-butylsulfonyl)quinazolin-7-yl)oxy)propan-2-ol,
N-(6-(*tert*-butylsulfonyl)-7-propoxyquinazolin-4-yl)benzo[*d*]thiazol-5-amine,
N-(6-(*tert*-butylsulfonyl)-7-(2-(methylthio)ethoxy)quinazolin-4-yl)benzo[*d*]thiazol-5-amine,

Example 9

3-{[4-(1,3-benzothiazol-5-ylamino)-6-quinazoliny]sulfonyl}-3-methyl-1-butanol



5

Step 1. 3-{[4-(1,3-benzothiazol-5-ylamino)-6-quinazoliny]thio}-3-methyl-1-butanol: To a solution of *N*-1,3-benzothiazol-5-yl-6-iodo-4-quinazolinamine (202 mg, 0.500 mmol), 3-mercapto-3-methyl-1-butanol (60 mg, 0.50 mmol), potassium *tert*-butoxide (168 mg, 1.50 mmol) and (oxydi-2,1-phenylene)bis(diphenyl phosphine) (27 mg, 0.05 mmol) in dioxane (4 mL) was added Pd₂dba₃ (46 mg, 0.05 mmol) and the mixture was sparged with N₂ for 10 min. The reaction was complete in 2 h. Solvent was removed and the crude material was purified *via* column chromatography (0 to 5% MeOH/CH₂Cl₂) to afford 142 mg of the title compound (72%). MS: *m/z*: 397 [M+H]⁺

Cesium carbonate may also be used as the base in these coupling reactions. An equivalent of triethamine may also be added when the starting quinazoline is an HCl salt.


Step 2. 3-{[4-(1,3-benzothiazol-5-ylamino)-6-quinazoliny]sulfonyl}-3-methyl-1-butanol: 3-{[4-(1,3-benzothiazol-5-ylamino)-6-quinazoliny]thio}-3-methyl-1-butanol (140 mg, 0.35 mmol) and oxone (434 mg, 0.71 mmol) were suspended in MeOH (2 mL) and the mixture was stirred at rt for 5 h. Upon filtration the cake was washed with MeOH and the filtrate was concentrated. The crude material was purified *via* column chromatography (0 to 8% MeOH/CH₂Cl₂) to afford 3-{[4-(1,3-benzothiazol-5-ylamino)-6-quinazoliny]sulfonyl}-3-methyl-1-butanol (67 mg, 0.15 mmol, 42% yield). MS: *m/z*: 429 [M+H]⁺; ¹H NMR (DMSO-*d*₆) δ: 10.66 (s, 1H), 9.44 (s, 1H), 9.25 (d, *J* = 1.5 Hz, 1H), 8.76 (s, 1H), 8.64 (d, *J* = 1.8 Hz, 1H), 8.13 - 8.30 (m, 2H), 7.89 - 8.07 (m, 2H), 4.58 (t, *J* = 4.8 Hz, 1H), 3.58 (d, *J* = 5.3 Hz, 2H), 1.86 (t, *J* = 6.9 Hz, 2H), 1.34 (s, 6H).

25

EtOH and water (1:1) may also be used as the solvent mixture.

CLAIMS

1. A compound according to Formula (I):



wherein:

R^1 is H, $-SO_2(C_1-C_4)alkyl$, $-CO(C_1-C_4)alkyl$, or $(C_1-C_4)alkyl$;

R^2 is $-SR^a$, $-SOR^a$, or $-SO_2R^a$, wherein R^a is $(C_1-C_6)alkyl$, $halo(C_1-C_6)alkyl$, $(C_3-C_7)cycloalkyl$, 4-7 membered heterocycloalkyl, aryl, or heteroaryl, wherein:

said $(C_1-C_6)alkyl$ is optionally substituted by one or two groups each independently selected from cyano, hydroxyl, $(C_1-C_6)alkoxy$, $(C_1-C_6)alkoxy(C_2-C_6)alkoxy$, $-CO_2H$, $-CO_2(C_1-C_4)alkyl$, $-SO_2(C_1-C_4)alkyl$, $(C_3-C_7)cycloalkyl$, phenyl, 5-6 membered heteroaryl, 9-10 membered heteroaryl, 4-7 membered heterocycloalkyl and $(phenyl)(C_1-C_4)alkylamino-$, wherein said $(C_3-C_7)cycloalkyl$, phenyl, $(phenyl)(C_1-C_4)alkylamino-$, 5-6 membered heteroaryl, 9-10 membered heteroaryl or 4-7 membered heterocycloalkyl is optionally substituted by 1-3 groups each independently selected from halogen, $-CF_3$, hydroxyl, amino, $((C_1-C_4)alkyl)amino-$, $((C_1-C_4)alkyl)((C_1-C_4)alkyl)amino-$, $(C_1-C_4)alkyl$, $phenyl(C_1-C_4)alkyl-$, $hydroxy(C_1-C_4)alkyl$ and $(C_1-C_4)alkoxy$,

said $(C_3-C_7)cycloalkyl$ or 4-7 membered heterocycloalkyl is optionally substituted by 1-3 groups each independently selected from halogen, $-CF_3$, hydroxyl, amino, $((C_1-C_4)alkyl)amino-$, $((C_1-C_4)alkyl)((C_1-C_4)alkyl)amino-$, $(C_1-C_4)alkyl$, $phenyl(C_1-C_4)alkyl-$, $hydroxy(C_1-C_4)alkyl-$, oxo and $(C_1-C_4)alkoxy$, and

said aryl or heteroaryl is optionally substituted by 1-3 groups each independently selected from halogen, $-CF_3$, hydroxyl, amino, $((C_1-C_4)alkyl)amino-$, $((C_1-C_4)alkyl)((C_1-C_4)alkyl)amino-$, $(C_1-C_4)alkyl$, $phenyl(C_1-C_4)alkyl-$, $hydroxy(C_1-C_4)alkyl-$ and $(C_1-C_4)alkoxy$;

R^3 is H, halogen, hydroxy, $(C_1-C_4)alkyl-$, $(C_2-C_4)alkenyl-$, $halo(C_1-C_4)alkyl-$, $(C_1-C_4)alkoxy-$, $halo(C_1-C_4)alkoxy-$, $(C_1-C_4)alkoxy(C_1-C_6)alkyl-$, $halo(C_1-C_4)alkoxy(C_1-C_6)alkyl-$, $(C_1-C_4)alkoxy(C_2-C_6)alkoxy-$, $halo(C_1-C_4)alkoxy(C_2-C_6)alkoxy-$, $hydroxy(C_1-C_6)alkyl-$, $hydroxy(C_2-C_6)alkoxy-$, $cyano(C_1-C_4)alkyl-$, $cyano(C_2-C_6)alkoxy-$, $carboxy-(C_1-C_6)alkoxy-$,

(C₁-C₄)alkoxycarbonyl(C₁-C₆)alkoxy-, (C₃-C₆)cycloalkyl(C₁-C₄)alkoxy-, (C₃-C₆)cycloalkoxy-, 4-6 membered-heterocycloalkyl(C₁-C₄)alkoxy-, or 4-6 membered-heterocycloalkoxy-,

wherein the halo(C₁-C₄)alkyl-, halo(C₁-C₄)alkoxy-, halo(C₁-C₄)alkoxy(C₁-C₆)alkyl-, or halo(C₁-C₄)alkoxy(C₂-C₆)alkoxy- groups contain 2 or 3 halo atoms; and

wherein the (C₃-C₆)cycloalkyl moiety of the (C₃-C₆)cycloalkyl(C₁-C₄)alkoxy- or (C₃-C₆)cycloalkoxy-, is optionally substituted by a group selected from cyano, halo, hydroxyl, (C₁-C₆)alkoxy and (C₁-C₄)alkoxy(C₂-C₆)alkoxy;

wherein the 4-6 membered-heterocycloalkyl moiety of the 4-6 membered-heterocycloalkyl(C₁-C₄)alkoxy-, or 4-6 membered-heterocycloalkoxy-, is optionally substituted by a group selected from cyano, halo, hydroxyl, (C₁-C₆)alkoxy and (C₁-C₄)alkoxy(C₂-C₆)alkoxy;

Z is aryl(C₁-C₄)alkyl-, substituted by R⁴, R⁵, R⁶ and R⁷, wherein:

R⁴ is H, halogen, cyano, (C₁-C₄)alkyl, halo(C₁-C₄)alkyl, (C₁-C₄)alkoxy, phenoxy, phenyl(C₁-C₄)alkoxy, hydroxyl, hydroxy(C₁-C₄)alkyl-, or aminocarbonyl, wherein the phenyl moiety of said phenoxy or phenyl(C₁-C₄)alkoxy- is optionally substituted by 1-3 substituents each independently selected from halogen, -CF₃, (C₁-C₄)alkyl and (C₁-C₄)alkoxy; and


each of R⁵, R⁶ and R⁷ is independently selected from H, hydroxyl, halogen, -CF₃, hydroxy(C₁-C₄)alkyl, (C₁-C₄)alkyl and (C₁-C₄)alkoxy; or

Z is phenyl or pyridyl substituted by R⁸, R⁹ and R¹⁰, wherein:

R⁸ and R⁹ are located on adjacent atoms and taken together with the atoms to which they are attached form a 5-membered heterocyclic group containing 1, 2 or 3 heteroatoms each independently selected from N, O and S, which 5-membered heterocyclic group is substituted by R¹¹;

wherein one of R¹⁰ or R¹¹ is H, halogen, cyano, (C₁-C₄)alkyl, halo(C₁-C₄)alkyl, (C₁-C₄)alkoxy, phenoxy, phenyl(C₁-C₄)alkoxy, hydroxyl, hydroxy(C₁-C₄)alkyl-, or aminocarbonyl, where the phenyl moiety of said phenoxy or phenyl(C₁-C₄)alkoxy is optionally substituted by 1-3 substituents each independently selected from halogen, -CF₃, (C₁-C₄)alkyl and (C₁-C₄)alkoxy; and

the other of R¹⁰ or R¹¹ is H, hydroxyl, halogen, -CF₃, hydroxy(C₁-C₄)alkyl, (C₁-C₄)alkyl or (C₁-C₄)alkoxy; or



Z is pyrazolyl, having the formula:

wherein:

R^{12} is H, methyl or hydroxymethyl;

R^{13} is methyl, trifluoromethyl or hydroxymethyl;

R^{14} is H, OH, or (C_1-C_3) alkyl; or

R^{12} and R^{13} , taken together with the atoms to which they are attached, form a 6 membered carbocyclic ring or heterocyclic ring substituted by R^{15} and R^{16} , wherein the heterocyclic ring contains 1 nitrogen atom; wherein R^{15} and R^{16} are each independently selected from H, halogen, cyano, (C_1-C_4) alkyl, halo (C_1-C_4) alkyl, (C_1-C_4) alkoxy, phenoxy, phenyl (C_1-C_4) alkoxy, hydroxyl, hydroxy (C_1-C_4) alkyl-, and aminocarbonyl, wherein the phenyl moiety of said phenoxy or phenyl (C_1-C_4) alkoxy is optionally substituted by 1-3 substituents each independently selected from halogen, $-CF_3$, (C_1-C_4) alkyl and (C_1-C_4) alkoxy;

provided that the compound is not:

N-[(3,4-difluorophenyl)methyl]-6-[(methylsulfonyl)-4-quinazolinamine,

N-[(3,4-dichlorophenyl)methyl]-6-(methylthio)-4-quinazolinamine,

N-[(3-fluoro-4-methoxyphenyl)methyl]-6-(methylthio)-4-quinazolinamine,

or a salt thereof.

2. The compound or salt according to claim 1, wherein R^1 is H.

3. The compound or salt according to claim 1 or claim 2, wherein R^2 is $-SO_2R^a$.

4. The compound or salt according to any one of claims 1-3, wherein R^a is a (C_1-C_6) alkyl group optionally substituted by a substituent selected from the group consisting of hydroxyl, (C_1-C_2) alkoxy, and (C_1-C_2) alkoxy (C_2-C_3) alkoxy- or R^a is a 5-6-membered heterocycloalkyl group optionally substituted by 1 or 2 independently selected (C_1-C_4) alkyl groups.

5. The compound or salt according to any one of claims 1-4, wherein R^a is $-CH_3$, $-CH(CH_3)_2$, $-C(CH_3)_3$, $-CH_2CH_2OH$, $-C(CH_3)_2CH_2CH_2OH$, or tetrahydro-2H-pyran-4-yl.

6. The compound or salt according to any one of claims 1-5, wherein R^3 is H, halogen, hydroxy, (C_1-C_3) alkyl-, (C_2-C_3) alkenyl-, halo (C_1-C_2) alkyl-, (C_1-C_4) alkoxy-, halo (C_1-C_3) alkoxy-, (C_5-C_6) cycloalkyl (C_1-C_3) alkoxy-, 5-6-membered-heterocycloalkyl-oxy-, (C_1-C_3) alkoxy (C_1-C_4) alkyl-, (C_1-C_3) alkoxy (C_2-C_4) alkoxy-, carboxy- (C_1-C_4) alkoxy-, (C_1-C_3) alkoxycarbonyl (C_1-C_4) alkoxy-, or hydroxy (C_2-C_4) alkoxy-.

7. The compound or salt according to any one of claims 1-5, wherein R^3 is H, chloro, $-CH_2CH_3$, $-CH=CH_2$, $-OH$, $-OCH_3$, $-OCF_2H$, $-OCH(CH_3)_2$, $-OCH_2CH_3$, $-OCH_2CF_3$, $-OCH_2CH_2Cl$, $-OCH_2CH_2OH$, $-OCH_2CH_2CH_2OH$, $-OCH_2CH_2OCH_3$, $-OC(CH_3)_2CH_2OH$, $-OCH(CH_3)CH_2OH$, $-OC(CH_3)_2CO_2CH_2CH_3$, cyclohexylmethoxy-, or tetrahydro-2H-pyran-4-yloxy-.

8. The compound or salt according to any one of claims 1-7, wherein Z is benzothiazolyl, optionally substituted by 1-3 substituents independently selected from the group consisting of halogen, (C_1-C_4) alkyl, halo (C_1-C_4) alkyl or (C_1-C_4) alkoxy.

9. The compound or salt according to any one of claims 1-7, wherein Z is pyrazolyl, R^{12} and R^{13} are each methyl, and R^{14} is H.

10. The compound or salt according to claim 1, wherein:

R^1 is H;

R^2 is $-SR^a$ or $-SO_2R^a$, and R^a is $-CH_3$, $-CH(CH_3)_2$, $-C(CH_3)_3$, $-CH_2CH_2OH$, $-C(CH_3)_2CH_2CH_2OH$, or tetrahydro-2H-pyran-4-yl;

R^3 is H, chloro, $-CH_2CH_3$, $-CH=CH_2$, $-OH$, $-OCH_3$, $-OCF_2H$, $-OCH(CH_3)_2$, $-OCH_2CH_3$, $-OCH_2CF_3$, $-OCH_2CH_2Cl$, $-OCH_2CH_2OH$, $-OCH_2CH_2CH_2OH$, $-OCH_2CH_2OCH_3$, $-OC(CH_3)_2CH_2OH$, $-OCH(CH_3)CH_2OH$, $-OC(CH_3)_2CO_2CH_2CH_3$, cyclohexylmethoxy-, or tetrahydro-2H-pyran-4-yloxy-; and

Z is benzo[d]thiazol-5-yl or 5-fluoro-1*H*-indazol-3-yl, or Z is pyrazolyl, wherein R¹² is H or methyl, R¹³ is methyl or trifluoromethyl, and R¹⁴ is H or methyl.

11. A compound according to claim 1 which is

N-1,3-benzothiazol-5-yl-6-[(1,1-dimethylethyl)thio]-4-quinazolinamine,
N-1,3-benzothiazol-5-yl-6-[(1,1-dimethylethyl)sulfonyl]-4-quinazolinamine,
6-(*tert*-butylsulfonyl)-*N*-(5-fluoro-1*H*-indazol-3-yl)quinazolin-4-amine,
N-1,3-benzothiazol-5-yl-6-[(1-methylethyl)sulfonyl]-4-quinazolinamine,
2-{[4-(1,3-benzothiazol-5-ylamino)-6-quinazolinyl]sulfonyl} ethanol,
N-1,3-benzothiazol-5-yl-6-(tetrahydro-2*H*-pyran-4-ylsulfonyl)-4-quinazolinamine,
N-1,3-benzothiazol-5-yl-6-(tetrahydro-2*H*-pyran-4-ylsulfonyl)-4-quinazolinamine,
2-((4-((4,5-dimethyl-1*H*-pyrazol-3-yl)amino)-7-methoxyquinazolin-6-yl)sulfonyl)ethanol,
N-(5-fluoro-1*H*-indazol-3-yl)-6-[(1-methylethyl)sulfonyl]-4-quinazolinamine,
N-(4,5-dimethyl-1*H*-pyrazol-3-yl)-6-[(1-methylethyl)sulfonyl]-4-quinazolinamine,
6-(*tert*-butylsulfonyl)-*N*-(5-(trifluoromethyl)-1*H*-pyrazol-3-yl)quinazolin-4-amine,
6-(*tert*-butylsulfonyl)-*N*-(1,3,4-trimethyl-1*H*-pyrazol-5-yl)quinazolin-4-amine,
N-(6-(*tert*-butylthio)-7-methoxyquinazolin-4-yl)benzo[d]thiazol-5-amine,
N-(6-(*tert*-butylsulfonyl)-7-methoxyquinazolin-4-yl)benzo[d]thiazol-5-amine,
N-(6-(isopropylsulfonyl)-7-methoxyquinazolin-4-yl)benzo[d]thiazol-5-amine,
4-(benzo[d]thiazol-5-ylamino)-6-(*tert*-butylsulfonyl)quinazolin-7-ol,
N-(6-(*tert*-butylsulfonyl)-7-ethoxyquinazolin-4-yl)benzo[d]thiazol-5-amine,
N-(6-(*tert*-butylsulfonyl)-7-ethoxyquinazolin-4-yl)-*N*-ethylbenzo[d]thiazol-5-amine,
2-((4-(benzo[d]thiazol-5-ylamino)-6-(*tert*-butylsulfonyl)quinazolin-7-yl)oxy)ethanol,
N-(6-(*tert*-butylsulfonyl)-7-(difluoromethoxy)quinazolin-4-yl)benzo[d]thiazol-5-amine,
N-(6-(*tert*-butylsulfonyl)-7-(2,2,2-trifluoroethoxy)quinazolin-4-yl)benzo[d]thiazol-5-amine,
N-(6-(*tert*-butylsulfonyl)-7-(methoxymethoxy)quinazolin-4-yl)benzo[d]thiazol-5-amine,
N-(6-(*tert*-butylsulfonyl)-7-(cyclohexylmethoxy)quinazolin-4-yl)benzo[d]thiazol-5-amine,
3-((4-(benzo[d]thiazol-5-ylamino)-6-(*tert*-butylsulfonyl)quinazolin-7-yl)oxy)propan-1-ol,
N-(6-(*tert*-butylsulfonyl)-7-((tetrahydro-2*H*-pyran-4-yl)oxy)quinazolin-4-yl)benzo[d]thiazol-5-amine,
N-(6-(*tert*-butylsulfonyl)-7-(2-chloroethoxy)quinazolin-4-yl)benzo[d]thiazol-5-amine,

(R)-1-((4-(benzo[d]thiazol-5-ylamino)-6-(*tert*-butylsulfonyl)quinazolin-7-yl)oxy)propan-2-ol,
N-(6-(*tert*-butylsulfonyl)-7-propoxyquinazolin-4-yl)benzo[d]thiazol-5-amine,
N-(6-(*tert*-butylsulfonyl)-7-(2-(methylthio)ethoxy)quinazolin-4-yl)benzo[d]thiazol-5-amine,
N-(7-(2-bromoethoxy)-6-(*tert*-butylsulfonyl)quinazolin-4-yl)benzo[d]thiazol-5-amine,
 4-(benzo[d]thiazol-5-ylamino)-6-(*tert*-butylthio)quinazolin-7-ol,
N-(6-(*tert*-butylthio)-7-isopropoxyquinazolin-4-yl)benzo[d]thiazol-5-amine,
N-(6-(*tert*-butylsulfonyl)-7-isopropoxyquinazolin-4-yl)benzo[d]thiazol-5-amine,
 ethyl 2-((4-(benzo[d]thiazol-5-ylamino)-6-(*tert*-butylsulfonyl)quinazolin-7-yl)oxy)-2-methylpropanoate,
 2-((4-(benzo[d]thiazol-5-ylamino)-6-(*tert*-butylsulfonyl)quinazolin-7-yl)oxy)-2-methylpropan-1-ol,
N-1,3-benzothiazol-5-yl-6-[(1,1-dimethylethyl)sulfonyl]-7-ethenyl-4-quinazolinamine,
N-1,3-benzothiazol-5-yl-6-[(1,1-dimethylethyl)sulfonyl]-7-ethyl-4-quinazolinamine,
N-(6-(*tert*-butylsulfonyl)-7-chloroquinazolin-4-yl)benzo[d]thiazol-5-amine,
 6-(*tert*-butylsulfonyl)-7-chloro-*N*-(4,5-dimethyl-1*H*-pyrazol-3-yl)quinazolin-4-amine,
 6-[(1,1-dimethylethyl)sulfonyl]-*N*-(5-fluoro-1*H*-pyrazolo[3,4-*b*]pyridin-3-yl)-7-(methyloxy)-4-quinazolinamine,
 6-(*tert*-butylsulfonyl)-*N*-(4-chloro-3-methoxyphenyl)-7-methoxyquinazolin-4-amine,
 5-((6-(*tert*-butylsulfonyl)-7-methoxyquinazolin-4-yl)amino)-2-chlorophenol,
 6-(*tert*-butylsulfonyl)-7-methoxy-*N*-(3-methyl-1*H*-indazol-6-yl)quinazolin-4-amine,
 6-(*tert*-butylsulfonyl)-*N*-(4-chloro-2-fluorophenyl)-7-methoxyquinazolin-4-amine,
 6-(*tert*-butylsulfonyl)-*N*-(1*H*-indazol-6-yl)-7-methoxyquinazolin-4-amine,
 6-(*tert*-butylsulfonyl)-*N*-(4,5-dimethyl-1*H*-pyrazol-3-yl)-7-methoxyquinazolin-4-amine,
 (E)-3-(4-(benzo[d]thiazol-5-ylamino)-6-(*tert*-butylsulfonyl)quinazolin-7-yl)prop-2-en-1-ol,
 2-((4-(benzo[d]thiazol-5-ylamino)-7-methoxyquinazolin-6-yl)sulfonyl)ethanol,
 (R)-methyl 2-((4-(benzo[d]thiazol-5-ylamino)-6-(*tert*-butylsulfonyl)quinazolin-7-yl)oxy)propanoate.
 (S)-methyl 2-((4-(benzo[d]thiazol-5-ylamino)-6-(*tert*-butylsulfonyl)quinazolin-7-yl)oxy)propanoate,
 methyl 2-((4-(benzo[d]thiazol-5-ylamino)-6-(*tert*-butylsulfonyl)quinazolin-7-yl)oxy)propanoate,
 (R)-2-((4-(benzo[d]thiazol-5-ylamino)-6-(*tert*-butylsulfonyl)quinazolin-7-yl)oxy)propan-1-ol,

(S)-2-((4-(benzo[d]thiazol-5-ylamino)-6-(*tert*-butylsulfonyl)quinazolin-7-yl)oxy)propan-1-ol,
 2-((4-(benzo[d]thiazol-5-ylamino)-6-(*tert*-butylsulfonyl)quinazolin-7-yl)oxy)propan-1-ol,
N-(6-(*tert*-butylsulfonyl)-7-methoxyquinazolin-4-yl)benzo[d]thiazol-5-amine,
 2-((4-(benzo[d]thiazol-5-ylamino)-6-(*tert*-butylsulfonyl)quinazolin-7-yl)oxy)acetamide,
 2-((4-(benzo[d]thiazol-5-ylamino)-6-(*tert*-butylsulfonyl)quinazolin-7-yl)oxy)acetic acid,
N-(6-(*tert*-butylsulfonyl)-7-(2-(methylsulfonyl)ethoxy)quinazolin-4-yl)benzo[d]thiazol-5-amine,
N-(6-(*tert*-butylsulfonyl)-7-(2-(isopropylsulfonyl)ethoxy)quinazolin-4-yl)benzo[d]thiazol-5-amine,
 (E)-methyl 3-((4-(benzo[d]thiazol-5-ylamino)-6-(*tert*-butylsulfonyl)quinazolin-7-yl)oxy)acrylate,
 (E)-3-((4-(benzo[d]thiazol-5-ylamino)-6-(*tert*-butylsulfonyl)quinazolin-7-yl)oxy)acrylamide,
 (E)-3-((4-(benzo[d]thiazol-5-ylamino)-6-(*tert*-butylsulfonyl)quinazolin-7-yl)oxy)acrylic acid,
N-(6-(*tert*-butylsulfonyl)-7-(vinyl)oxy)quinazolin-4-yl)benzo[d]thiazol-5-amine,
 4-(benzo[d]thiazol-5-ylamino)-7-methoxy-*N,N*-dimethylquinazoline-6-sulfonamide,
 4-(benzo[d]thiazol-5-ylamino)-*N*-isopropyl-7-methoxyquinazoline-6-sulfonamide,
N-(7-methoxy-6-(pyrrolidin-1-ylsulfonyl)quinazolin-4-yl)benzo[d]thiazol-5-amine,
N-(7-methoxy-6-(morpholin-4-ylsulfonyl)quinazolin-4-yl)benzo[d]thiazol-5-amine,
 4-(benzo[d]thiazol-5-ylamino)-*N*-(2-hydroxyethyl)-7-methoxyquinazoline-6-sulfonamide,
 4-(benzo[d]thiazol-5-ylamino)-7-methoxy-*N*-(tetrahydro-2*H*-pyran-4-yl)quinazoline-6-sulfonamide,
 4-(benzo[d]thiazol-5-ylamino)-*N*-(2-hydroxy-2-methylpropyl)-7-methoxyquinazoline-6-sulfonamide,
 1-((4-(benzo[d]thiazol-5-ylamino)-7-methoxyquinazolin-6-yl)sulfonyl)pyrrolidin-3-ol,
 4-(benzo[d]thiazol-5-ylamino)-*N*-(2-hydroxypropyl)-7-methoxyquinazoline-6-sulfonamide,
 4-(benzo[d]thiazol-5-ylamino)-7-methoxy-*N*-(2-methoxyethyl)quinazoline-6-sulfonamide,
 4-(benzo[d]thiazol-5-ylamino)-7-methoxy-*N*-(oxetan-3-yl)quinazoline-6-sulfonamide,
 4-(benzo[d]thiazol-5-ylamino)-*N*-(2-(dimethylamino)ethyl)-7-methoxyquinazoline-6-sulfonamide,
 1-((4-(benzo[d]thiazol-5-ylamino)-7-methoxyquinazolin-6-yl)sulfonyl)pyrrolidine-2-carboxylic acid,
 1-(4-((4-(benzo[d]thiazol-5-ylamino)-7-methoxyquinazolin-6-yl)sulfonyl)piperazin-1-yl)ethanone,
N-(2-(1*H*-tetrazol-5-yl)ethyl)-4-(benzo[d]thiazol-5-ylamino)-7-methoxyquinazoline-6-

sulfonamide,
4-(benzo[d]thiazol-5-ylamino)-7-methoxy-*N*-((tetrahydro-2*H*-pyran-4-yl)methyl)quinazolin-6-
sulfonamide,
or a salt thereof.

12. A compound according to claim 11 which is 2-((4-(benzo[d]thiazol-5-ylamino)-6-(*tert*-butylsulfonyl)quinazolin-7-yl)oxy)ethanol, or a salt thereof.

13. The compound or salt according to any one of claims 1-12, wherein the salt is a pharmaceutically acceptable salt of said compound.

14. A pharmaceutical composition comprising the compound or pharmaceutically acceptable salt thereof according to claim 13, and one or more pharmaceutically acceptable excipients.

15. A pharmaceutical composition according to claim 14, which further comprises one or more additional pharmaceutically active compounds.

16. A compound or pharmaceutically acceptable salt thereof according to claim 13, for use in therapy.

17. A compound or pharmaceutically acceptable salt thereof according to claim 13, for use in the treatment of a RIP2 kinase-mediated disease or disorder which is selected from uveitis, interleukin-1 converting enzyme associated fever syndrome, dermatitis, acute lung injury, type 2 diabetes mellitus, arthritis, rheumatoid arthritis, an inflammatory bowel disorder, ulcerative colitis, Crohn's disease, early-onset and extra-intestinal inflammatory bowel disease, prevention of ischemia reperfusion injury in solid organ transplant, non-alcohol steatohepatitis, alcohol steatohepatitis, autoimmune hepatitis, asthma, graft versus host disease, systemic lupus erythematosus, multiple sclerosis, sarcoidosis, Blau syndrome/early-onset sarcoidosis, Wegner's granulomatosis, and interstitial pulmonary disease.

18. A compound or pharmaceutically acceptable salt thereof for use according to claim 17, wherein the disease or disorder is Blau Syndrome.

19. A compound or pharmaceutically acceptable salt thereof for use according to claim 17, wherein the disease or disorder is ulcerative colitis.

20. A compound or pharmaceutically acceptable salt thereof for use according to claim 17, wherein the disease or disorder is Crohn's disease.

21. A compound or pharmaceutically acceptable salt thereof for use according to claim 17, wherein the disease or disorder is rheumatoid arthritis.

22. Use of the compound or pharmaceutically acceptable salt thereof according to claim 13, in the manufacture of a medicament for the treatment of a RIP2 Kinase-mediated disease or disorder which is selected from uveitis, interleukin-1 converting enzyme associated fever syndrome, dermatitis, acute lung injury, type 2 diabetes mellitus, arthritis, rheumatoid arthritis, an inflammatory bowel disorder, ulcerative colitis, Crohn's disease, early-onset and extra-intestinal inflammatory bowel disease, prevention of ischemia reperfusion injury in solid organ transplant, non-alcohol steatohepatitis, alcohol steatohepatitis, autoimmune hepatitis, asthma, graft versus host disease, systemic lupus erythematosus, multiple sclerosis, sarcoidosis, Blau syndrome/early-onset sarcoidosis, Wegner's granulomatosis, and interstitial pulmonary disease.